Nasonex Related Published Studies
Well-designed clinical trials related to Nasonex (Mometasone Nasal)
Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma. [2011.10]
Dysphagia and quality of life may improve with mometasone treatment in patients with eosinophilic esophagitis: a pilot study. [2011.10]
Application of mometasone spray to reduce sore throat after tracheal intubation. [2011.08]
The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. [2011.06]
Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. [2011.04.01]
Efficacy and safety of mometasone furoate nasal spray in the treatment of chronic rhinosinusitis. [2011.03]
Effects of mometasone furoate on the quality of life: a randomized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire. [2011.03]
Mometasone furoate effect on acute skin toxicity in breast cancer patients
receiving radiotherapy: a phase III double-blind, randomized trial from the North
Central Cancer Treatment Group N06C4. [2011]
Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. [2010.12]
Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. [2010.11]
Intranasal mometasone furoate therapy for allergic rhinitis symptoms and rhinitis-disturbed sleep. [2010.07]
Efficacy and safety of two dry-powder inhalers for the administration of mometasone furoate in asthma patients. [2010.07]
Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis. [2010.06]
Daily versus self-adjusted dosing of topical mometasone furoate nasal spray in patients with allergic rhinitis: randomised, controlled trial. [2010.04]
Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. [2010.01.05]
Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. [2010.01]
Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis. [2010.01]
Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10
microg and 400/10 microg combination treatments in patients with persistent
asthma previously receiving high-dose inhaled corticosteroids. [2010]
Comparison of patient preference for sensory attributes of fluticasone furoate or
fluticasone propionate in adults with seasonal allergic rhinitis: a randomized,
placebo-controlled, double-blind study. [2010]
Use of mometasone furoate administered via a dry powder inhaler in the treatment
of asthma. [2010]
Treatment of postviral olfactory loss with glucocorticoids, Ginkgo biloba, and mometasone nasal spray. [2009.10]
Once-Daily Evening Dosing of Mometasone Furoate Administered Via a Dry Powder Inhaler Does Not Adversely Affect the Hypothalamic-Pituitary-Adrenal Axis. [2009.09.14]
Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. [2009.08]
Effect of the inhaled corticosteroid mometasone on small airway patency in patients with asthma. [2009.05]
Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. [2009.05]
Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery. [2009.03]
One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. [2008.11.13]
Intranasal Mometasone Furoate Alleviates the Ocular Symptoms Associated with Seasonal Allergic Rhinitis: Results of a Post Hoc Analysis. [2008.07.12]
Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial. [2008.04]
Onset of symptomatic effect of mometasone furoate nasal spray in the treatment of nasal polyposis. [2008.04]
Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. [2008.03]
Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. [2008.03]
[Patient preference survey on the lack of taste and odor of Nasonex nasal spray. Which impact on compliance to treatment?] [2008]
Intranasal mometasone furoate alleviates the ocular symptoms associated with seasonal allergic rhinitis: results of a post hoc analysis. [2008]
Phimotic ring topical corticoid cream (0.1% mometasone furoate) treatment in children. [2007.10]
Effect of mometasone furoate nasal spray on quality of life of patients with acute rhinosinusitis. [2007.09]
The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study. [2007.06]
The Role of Mometasone Furoate Aqueous Nasal Spray in the Treatment of Adenoidal Hypertrophy in the Pediatric Age Group: Preliminary Results of a Prospective, Randomized Study. [2007.05.28]
Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. [2007.03]
Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. [2006.11]
Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. [2006.07.25]
The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo-controlled study. [2006.06]
Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. [2006.05]
Once-daily evening administration of mometasone furoate in asthma treatment initiation. [2006.04]
A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis. [2006.02]
Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. [2005.12]
Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. [2005.12]
Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. [2005.12]
Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. [2005.09]
Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. [2005.08]
Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. [2005.07]
Comparative potency of formulations of mometasone furoate in terms of inhibition of 'PIRHR' in the forearm skin of normal human subjects measured with laser doppler velocimetry. [2005.05]
Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. [2005.03]
A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. [2005]
Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. [2004.11.01]
Efficacy and systemic tolerability of mometasone furoate and betamethasone sodium phosphate. [2004.11]
Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. [2004.07]
Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. [2004.06]
Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. [2003.10]
Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. [2003.09]
Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. [2003.08]
Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma. [2003.06]
Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. [2003.04]
Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis. [2003.03]
A comparison of nasal clearance after treatment of perennial allergic rhinitis with budesonide and mometasone. [2003.02]
Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. [2002.09]
Comparison of mometasone furoate administered by metered dose inhaler with beclomethasone dipropionate. [2002.07]
A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. [2002.06]
Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. [2002.01]
Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. [2001.08.15]
The effectiveness of wet wrap dressings using 0.1% mometasone furoate and 0.005% fluticasone proprionate ointments in the treatment of moderate to severe atopic dermatitis in children. [2001.07]
Mometasone furoate nasal spray in the treatment of perennial non-allergic rhinitis: a nordic, multicenter, randomized, double-blind, placebo-controlled study. [2001.06]
Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study. [2001.06]
Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. [2001.04]
Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. [2001.04]
Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. [2001.02]
Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. [2001.01]
Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. [2000.12]
Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. [2000.11]
Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. [2000.11]
Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. [2000.11]
A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. [2000.10]
Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. The Nasonex Sinusitis Group. [2000.10]
Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. [2000.09]
Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. [2000.05]
Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. [2000.04]
Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. [2000.02]
[Changes in intraocular pressure with the use of topical nasal mometasone furoate] [2000.01]
Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. [1999.11]
Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. [1999.09]
A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. [1999.07]
The therapeutic efficacy of mometasone furoate cream 0.1% applied once daily vs clobetasol propionate cream 0.05% applied twice daily in chronic eczema. [1999.05]
Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. [1999.05]
Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. [1999.05]
Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. [1999.01]
Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. [1999.01]
Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. [1998.11]
Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. [1998.07]
[Mometasone and calcipotriol optimize the initial therapeutic effect of dithranol in chronic persistent psoriasis] [1998.04]
Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. [1998.03]
Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. [1998.03]
|
